Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma

被引:9
作者
Minematsu, Tsuyoshi [1 ]
Felder, Laurie [2 ]
Oppeneer, Todd [2 ]
Sakazume, Masashi [3 ]
Oikawa, Keishi [4 ]
Hashimoto, Tadashi [1 ]
Usui, Takashi [1 ]
Kamimura, Hidetaka [1 ]
机构
[1] Astellas Pharma Inc, Drug Metab Res Labs, Itabashi Ku, Tokyo 1748511, Japan
[2] Covance Labs Inc, Madison, WI USA
[3] Astellas Res Technol Co Ltd, Tokyo, Japan
[4] Astellas Pharma Inc, Clin Pharmacol, Tokyo, Japan
关键词
YM155; bioanalytical method; LC-MS/MS; validation; pharmacokinetics; dog plasma;
D O I
10.1002/bmc.996
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This paper describes a sensitive and selective liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for determination of the novel survivin suppressant YM155, 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, which is developed for the treatment of solid tumors. This method uses a liquid-liquid extraction from 0.25 mL of dog plasma. LC separation was carried out on a Genesis Silica column (50 mm x 3.0 mm i.d.) at a flow-rate of 0.5 mL/min. Compounds were eluted using a mobile phase of 5 mm ammonium acetate and 0.1% formic acid in water-0.1% formic acid in acetonitrile, 17:83 (v/v). MS/MS detection was carried out with an MDS-Sciex API3000 triple quadrupole mass spectrometer in positive electrospray ionization mode. The standard curve was linear from 0.05 to 50 ng/mL (r >= 0.9968). The lower limit of quantitation was 0.05 ng/mL. Good intra- and inter-day assay precision (within 7.4% RSD) and accuracy (within +/- 12.3%) were obtained. The extraction recovery was 66.2%. The method was successfully applied to preelinical pharmacokinetic studies in dogs. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:763 / 769
页数:7
相关论文
共 21 条
[11]   Broad spectrum and potent anti tumor activity of YM155, a novel small molecule survivin suppressant, against a large scale panel of human tumor cell lines [J].
Nakahara, T. ;
Takeuchi, M. ;
Kita, A. ;
Yamanaka, K. ;
Koutoku, H. ;
Kinoyama, I. ;
Matsuhisa, A. ;
Sasamata, M. .
EJC SUPPLEMENTS, 2006, 4 (12) :122-122
[12]   YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts [J].
Nakahara, Takahito ;
Takeuchi, Masahiro ;
Kinoyama, Isao ;
Minematsu, Tsuyoshi ;
Shirasuna, Kenna ;
Matsuhisa, Akira ;
Kita, Aya ;
Tominaga, Fumiko ;
Yamanaka, Kentaro ;
Kudoh, Masafumi ;
Sasamata, Masao .
CANCER RESEARCH, 2007, 67 (17) :8014-8021
[13]   Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin [J].
O'Connor, DS ;
Grossman, D ;
Plescia, J ;
Li, FZ ;
Zhang, H ;
Villa, A ;
Tognin, S ;
Marchisio, PC ;
Altieri, DC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (24) :13103-13107
[14]   The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral-inhibitor of apoptosis proteins [J].
Rothe, M ;
Pan, MG ;
Henzel, WJ ;
Ayres, TM ;
Goeddel, DV .
CELL, 1995, 83 (07) :1243-1252
[15]   The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases [J].
Roy, N ;
Deveraux, QL ;
Takahashi, R ;
Salvesen, GS ;
Reed, JC .
EMBO JOURNAL, 1997, 16 (23) :6914-6925
[16]   Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma [J].
Sarela, AI ;
Macadam, RCA ;
Farmery, SM ;
Markham, AF ;
Guillou, PJ .
GUT, 2000, 46 (05) :645-650
[17]  
Tamm I, 1998, CANCER RES, V58, P5315
[18]  
Tanaka K, 2000, CLIN CANCER RES, V6, P127
[19]  
Tolcher AW, 2006, J CLIN ONCOL, V24, p124S
[20]  
Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602